ALK-Abelló
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
ALK | CO
Overview
Corporate Details
- ISIN(s):
- DK0061802139
- LEI:
- 529900SGCREUZCZ7P020
- Country:
- Denmark
- Address:
- Bøge Alle 6-8, 2970 Hørsholm
- Website:
- https://www.alk.net
- Sector:
- Manufacturing
Description
ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-08-11 07:29 | English | PDF • 323.3 KB | |||
| 2022-08-11 07:29 |
Six-month interim report (Q2) 2022
|
Danish | HTML • 6.0 KB | ||
| 2022-08-11 07:29 |
Six-month interim report (Q2) 2022
|
Danish | HTML • 5.9 KB | ||
| 2022-08-04 13:37 | Danish | PDF • 98.6 KB | |||
| 2022-08-04 13:37 | English | HTML • 2.3 KB | |||
| 2022-08-04 13:37 |
ALK upgrades its full-year financial outlook
|
Danish | HTML • 2.4 KB | ||
| 2022-08-04 13:37 |
ALK upgrades its full-year financial outlook
|
Danish | PDF • 100.8 KB | ||
| 2022-06-27 12:44 | Danish | PDF • 202.9 KB | |||
| 2022-06-27 12:44 | English | PDF • 204.7 KB | |||
| 2022-06-27 12:44 |
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
|
Danish | HTML • 5.8 KB | ||
| 2022-06-27 12:44 |
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
|
Danish | HTML • 5.6 KB | ||
| 2022-05-19 18:15 | Danish | PDF • 132.9 KB | |||
| 2022-05-19 18:15 | English | PDF • 133.7 KB | |||
| 2022-05-19 18:15 |
Report on transactions with ALK-Abelló A/S B-shares and associated securities b…
|
Danish | HTML • 1.5 KB | ||
| 2022-05-19 18:15 |
Report on transactions with ALK-Abelló A/S B-shares and associated securities b…
|
Danish | HTML • 1.5 KB |
Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALK-Abelló
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALK-Abelló via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
